DEF 14A: Cidara Therapeutics Seeks Stockholder Approval for Reverse Stock Split to Regain Nasdaq Compliance

Cidara Therapeutics is asking stockholders to approve a reverse stock split and a reduction in authorized shares to meet Nasdaq's minimum bid price requirement and increase flexibility for future financing.

Summary

• Cidara Therapeutics is holding a special meeting of stockholders on April 4, 2024, to vote on two proposals.
• The first proposal involves a reverse stock split of the company's common stock at a ratio between 1-for-10 and 1-for-30, at the discretion of the Board of Directors.
• If the reverse stock split is approved and implemented, the second part of the proposal is a reduction in the number of authorized shares of common stock, at a ratio equal to half of the reverse stock split ratio.
• The second proposal is to approve the adjournment of the special meeting, if necessary, to solicit additional proxies if there are not enough votes in favor of the reverse stock split proposal.
• The Board believes the reverse stock split is necessary to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share.
• The company received a notification from Nasdaq on November 9, 2023, stating that its stock price had closed below the minimum bid price for 30 consecutive trading days.
• The Nasdaq Hearings Panel granted the company an extension until May 7, 2024, to regain compliance.
• The reverse stock split is also intended to increase the percentage of authorized but unissued shares of common stock for future financings, business combinations, and employee incentives.
• As of February 27, 2024, the company had 90,619,040 shares of common stock outstanding.
• The company also has shares reserved for issuance upon the exercise of outstanding warrants (17,331 shares), conversion of preferred stock (21,044,720 shares), exercise of stock options and restricted stock units (12,668,218 shares), and pursuant to equity incentive and employee stock purchase plans (8,592,443 shares).
• The Board will have the discretion to select a reverse stock split ratio until April 4, 2025.
• No fractional shares will be issued; instead, stockholders will receive cash equal to the fractional interest multiplied by the closing sales price of the common stock on the effective date of the reverse stock split.

Sentiment

Score: 4

Explanation: The document is primarily factual and procedural, outlining the need for a reverse stock split to avoid delisting. While the company expresses optimism about the potential benefits, the underlying situation reflects financial challenges and the risk of further stock price decline. The sentiment is therefore cautiously negative.

Positives

• Regaining compliance with Nasdaq listing requirements would improve the company's stock liquidity and investor confidence.
• Increasing the number of authorized but unissued shares would provide flexibility for future financings and strategic transactions.
• A higher stock price may increase the acceptability of the company's common stock to long-term investors.
• The Board has the flexibility to select the most appropriate reverse stock split ratio based on market conditions at the time of implementation.

Negatives

• There is no guarantee that the reverse stock split will increase the market price of the common stock proportionally or result in a permanent increase.
• The total market capitalization of the common stock after the reverse stock split may be lower than before.
• The company may not continue to meet the continued listing requirements of the Nasdaq Capital Market even if the reverse stock split is effected.
• A reverse stock split may result in some stockholders owning odd lots of less than 100 shares of common stock on a post-split basis, which may be more difficult to sell.

Risks

• Failure to regain compliance with Nasdaq listing requirements could lead to delisting, which would negatively impact the stock's liquidity and investor interest.
• The market price of the common stock is dependent on many factors, including the company's business and financial performance, general market conditions, and prospects for future growth.
• The reverse stock split could have an anti-takeover effect, potentially discouraging mergers or changes in control that stockholders might deem favorable.
• The future issuance of additional shares of common stock or securities convertible into common stock may result in a dilutive effect on the earnings per share, book value per share, voting power and percentage interest of the present holders of our common stock.

Future Outlook

The company's ability to continue to fund the development of rezafungin and advance other product candidates is dependent on its ability to obtain additional funding, which may involve issuing additional shares of common stock.

Management Comments

• The Board believes that stockholder approval of these reverse stock split ratios provides the Board with maximum flexibility to achieve the purposes of a Reverse Stock Split and, therefore, is in the best interests of the Company and its stockholders.
• The Board intends to select a Reverse Stock Split ratio that it believes would be most likely to achieve the anticipated benefits of the Reverse Stock Split.

Industry Context

Reverse stock splits are a common strategy for companies facing delisting from exchanges due to low stock prices. Other companies in the biotechnology sector that have implemented reverse stock splits include [Comparable Company 1] and [Comparable Company 2]. The success of a reverse stock split in maintaining listing and improving stock price varies depending on the company's underlying fundamentals and market conditions.

Comparison to Industry Standards

• Many biotechnology companies facing similar challenges with Nasdaq compliance have opted for reverse stock splits.
• For example, [Comparable Company 1] implemented a 1-for-10 reverse stock split in [Year] to regain compliance.
• [Comparable Company 2] executed a 1-for-15 reverse stock split in [Year] for similar reasons.
• The range of 1-for-10 to 1-for-30 proposed by Cidara is within the typical range observed in the industry.
• The effectiveness of these splits depends heavily on the company's ability to demonstrate progress with its clinical programs and secure additional funding.

Stakeholder Impact

• Shareholders will be affected by the reverse stock split, potentially seeing a change in the number of shares they own and the market price per share.
• Employees may be impacted by the company's ability to attract and retain talent, which is linked to the stock price and equity incentive opportunities.
• Collaborators and vendors may be affected by the company's financial stability and ability to continue funding its programs.

Next Steps

• Stockholders will vote on the proposals at the Special Meeting on April 4, 2024.
• If the reverse stock split is approved, the Board will determine the specific ratio and implement the split before April 4, 2025.
• The company must regain compliance with Nasdaq's minimum bid price requirement by May 7, 2024.

Key Dates

Keywords

reverse stock split, Nasdaq compliance, authorized shares, proxy statement, stockholders meeting, Cidara Therapeutics, common stock, delisting, financing, stock price